Toll-like receptors

Research

George Church launches startup aimed at safer gene therapy

A Harvard team led by George Church founded Ally Therapeutics to develop a way to "cloak" viral vectors from immune surveillance.
Angus Liu Feb 10, 2021 2:00pm

Stopping cancer before it develops

Jun 5, 2019 2:00pm

Idera’s TLR9-Yervoy combo works in PD-1-refractory melanoma

Dec 14, 2018 10:48am

Targeting Alzheimer’s with a soluble toll-like receptor

Aug 29, 2018 10:19am

Checkmate's I-O combo reverses PD-1 resistance in melanoma

Apr 17, 2018 9:37am

Targeting a toll-like receptor could attack the root cause of lupus

Jan 26, 2018 3:25pm